http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2499254-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aac4a747e60a2949ac458ccdbb76fdea |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-608 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2420-08 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-915 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-966 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 |
| filingDate | 2005-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77b9150e5b5e17340275454cc3bebc53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f83a23276ac294c4d9bc443c054bdc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_306a212ff074458afe717a5b3d5e167d |
| publicationDate | 2005-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2499254-A1 |
| titleOfInvention | Local vascular delivery of 2-methoxyestradiol in combination with rapamycin to prevent restenosis following vascular injury |
| abstract | Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reacti on to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduc e the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascul ar wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. |
| priorityDate | 2004-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 501.